ACTION-1
Tests whether an actinium alpha-radioligand rescues neuroendocrine tumours after lutetium therapy fails.
Phase 1b established 10.2 MBq fixed dose with encouraging responses; phase 3 enrolling with interim analysis expected 2026. Dosimetry published in J Nucl Med 2026.
Setting
SSTR-positive GEP-NETs progressing after 177Lu somatostatin-analogue therapy: 225Ac-DOTATATE (RYZ101) vs investigator's choice
Phase
Phase 3
Sponsor
BMS (RayzeBio)
Registry
Pages like this
not linked directly; found by shared links- TrialALPHAMEDIX-02
Shares Beta PRRT → alpha PRRT, Targeted alpha therapy, Neuroendocrine tumours.
- CompanyRayzeBio (BMS)
Shares Actinium-225 DOTATATE, Targeted alpha therapy, Neuroendocrine tumours.
- PairingBeta radioligand → alpha radioligand
Shares Actinium-225 DOTATATE, Lutetium-177 dotatate, Targeted alpha therapy, Neuroendocrine tumours.
- Product212Pb-DOTAMTATE
Shares Beta PRRT → alpha PRRT, Targeted alpha therapy, Neuroendocrine tumours.
- InstitutionChulabhorn Hospital / Chulabhorn Royal Academy
Shares Lutetium-177 dotatate, Targeted alpha therapy, Neuroendocrine tumours.
- IdeaRecover legacy radium-226 sources worldwide as the feedstock for actinium-225
- PersonEmily K. Bergsland
- InstitutionHolden Comprehensive Cancer Center, University of Iowa